Emgality

RSS

galcanezumab

Authorised
This medicine is authorised for use in the European Union.

Overview

Emgality is a medicine used to prevent migraine in adults who have migraines at least 4 days a month. It contains the active substance galcanezumab.

This EPAR was last updated on 11/11/2022

Authorisation details

Product details
Name
Emgality
Agency product number
EMEA/H/C/004648
Active substance
Galcanezumab
International non-proprietary name (INN) or common name
galcanezumab
Therapeutic area (MeSH)
Migraine Disorders
Anatomical therapeutic chemical (ATC) code
N02
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Eli Lilly Nederland B.V.
Revision
9
Date of issue of marketing authorisation valid throughout the European Union
14/11/2018
Contact address

Papendorpseweg 83
3528 BJ Utrecht
Netherlands

Product information

11/11/2022 Emgality - EMEA/H/C/004648 - IAIN/0020/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Analgesics

  • galcanezumab

Therapeutic indication

Emgality is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
Average
3 ratings